Join
Live feed
·
PRReleasevia Quantisnow
vTv Therapeutics Inc. logo

vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)

ByQuantisnow·Wall Street's wire, on your screen.
VTVT· vTv Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTVT (vTv Therapeutics Inc.) and more on Quantisnow.